Moreover, the EGFR and MUC16 mutations were also significantly enriched in cases within high‐risk group, while mutations in CIC, NOTCH1, ATRX, and CDH12 occurred more frequently in the low‐risk group (Figure 4B), these characteristics are consistent with the update WHO CNS5 classification of glioma. This evidence concerns the gene EGFR and glioma.